公开(公告)号：US20170122957A1

公开(公告)日：2017-05-04

申请号：US15404861

申请日：2017-01-12

Applicant: OLYMPUS CORPORATION

Inventor： Hiromi SANUKI ,  Mari NAKATA ,  Tetsuhide TAKEYAMA

IPC: G01N33/68

CPC classification number: G01N33/68 ,  G01N33/48

Abstract: A method of determining pancreatic disease of the present invention is a method of determining whether an IPMN patient has pancreatic disease, the method including: a first step of measuring a concentration of S100P in duodenal juice of the IPMN patient; and a second step of determining the IPMN patient is a malignant IPMN patient or a pancreatic cancer patient when the concentration of the S100P is equal to or greater than a predetermined cutoff value, and the IPMN patient is a benign IPMN patient when the concentration of the S100P is smaller than the predetermined cutoff value.

公开(公告)号：US20180238906A1

公开(公告)日：2018-08-23

申请号：US15961012

申请日：2018-04-24

Applicant: OLYMPUS CORPORATION

Inventor： Mari NAKATA ,  Hiromi SANUKI ,  Tetsuhide TAKEYAMA ,  Shoji TOKUNAGA ,  Masao TANAKA

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N33/48 ,  G01N33/68 ,  G01N2333/4727 ,  G01N2800/50

Abstract: The purpose of the present invention is to provide a method for evaluating the possibility of suffering from pancreatic disease on the basis of the concentration of a pancreatic disease marker in a duodenal juice sample. The method for evaluating the possibility of suffering from pancreatic disease of the present invention has a step for (a) measuring the concentration of the pancreatic disease marker in a duodenal juice sample taken from a subject and a step for (b) evaluating the possibility of the subject suffering from pancreatic disease on the basis of the concentration of the pancreatic disease marker measured in step (a) and the age of the subject.

公开(公告)号：US20140186869A1

公开(公告)日：2014-07-03

申请号：US14200188

申请日：2014-03-07

Applicant: OLYMPUS CORPORATION

Inventor： Rie KATAOKA ,  Mari NAKATA ,  Nao MORIYA

IPC: C12Q1/37

CPC classification number: C12Q1/37 ,  A01N1/00 ,  C07K14/81

Abstract: This method for inhibiting protease in a biological sample containing pancreatic juice components inhibits protease enzyme activity in the biological sample by adding at least one type of protease inhibitor having a sulfonyl fluoride group to the biological sample containing pancreatic juice components. In addition, this protease inhibitor for a biological sample containing pancreatic juice components is a compound having a sulfonyl fluoride group, has protease inhibitory activity, and is added to a biological sample containing pancreatic juice components in order to inhibit protease present in the biological sample. Moreover, this kit for preserving a biological sample containing pancreatic juice components contains at least one type of protease inhibitory having a sulfonyl fluoride group, and is used to store a biological sample containing pancreatic juice components.

Abstract translation: 用于抑制含有胰液成分的生物样品中的蛋白酶的方法通过向含有胰液成分的生物样品中添加至少一种具有磺酰氟基团的蛋白酶抑制剂来抑制生物样品中的蛋白酶活性。 此外，这种含有胰液成分的生物样品的蛋白酶抑制剂是具有磺酰氟基团的化合物，具有蛋白酶抑制活性，并且添加到含有胰液成分的生物样品中以抑制存在于生物样品中的蛋白酶。 此外，用于保存含有胰汁成分的生物样品的该试剂盒含有至少一种具有磺酰氟基团的蛋白酶抑制剂，并用于储存含有胰汁成分的生物样品。

公开(公告)号：US20170045518A1

公开(公告)日：2017-02-16

申请号：US15335309

申请日：2016-10-26

Applicant: OLYMPUS CORPORATION

Inventor： Mari NAKATA

IPC: G01N33/574

CPC classification number: G01N33/57438 ,  C12Q1/04 ,  G01N33/50 ,  G01N33/68 ,  G01N2333/4727 ,  G01N2333/70596 ,  G01N2400/00

Abstract: A method for suggesting a stage of progression of pancreatic cancer, includes: a first process of measuring a concentration of S100P or CEA in the duodenal juice; a second process of measuring a concentration of CA19-9 in a blood sample of the subject; and a third process of comparing the concentration of S100P or CEA with a first cutoff value, comparing the concentration of CA19-9 with a second cutoff value, suggesting the stage of progression of the pancreatic cancer based on the concentration of the S100P or CEA as an early stage, as a middle stage, or as a stage more progressed than the middle stage.

Abstract translation: 一种建议胰腺癌进展阶段的方法，包括：测量十二指肠液中S100P或CEA浓度的第一个过程; 测量受试者血液样本中CA19-9浓度的第二过程; 以及将S100P或CEA的浓度与第一截止值进行比较的第三过程，将CA19-9的浓度与第二截断值进行比较，表明基于S100P或CEA的浓度的胰腺癌进展阶段为 早期阶段，中间阶段，或阶段比中期更进步。

公开(公告)号：US20160116476A1

公开(公告)日：2016-04-28

申请号：US14981144

申请日：2015-12-28

Applicant: OLYMPUS CORPORATION

Inventor： Rie TAKEICHI ,  Nao SHIMADA ,  Hiromi SANUKI ,  Mari NAKATA ,  Masanobu KIYOHARA ,  Tetsuhide TAKEYAMA ,  Tomonori NAGAOKA

IPC: G01N33/574 ,  G01N21/29 ,  G01N33/68 ,  G01N21/31

CPC classification number: G01N33/57438 ,  A61B5/1032 ,  A61B5/4283 ,  A61B2010/0061 ,  G01N21/29 ,  G01N21/293 ,  G01N21/31 ,  G01N33/48 ,  G01N33/6872 ,  G01N2333/70503 ,  G01N2800/067

Abstract: Provided are a method for exclusively selecting a duodenal fluid sample having a high possibility of containing pancreatic fluid and favorable sample suitability for subjecting to detection of a pancreatic disease marker by evaluating the quality of the sample prior to detecting the pancreatic disease marker, and a method for detecting a pancreatic disease marker using a duodenal fluid sample selected according to that method. Namely, a method is provided for selecting a duodenal fluid sample for detecting a pancreatic disease marker, comprising: (a1) a step of comparing the color depth of a duodenal fluid sample with a prescribed standard color, and (b1) a step of determining that a duodenal fluid sample is subjected to a test for a pancreatic disease marker if the color depth thereof is equal to or higher than the standard color, but that the duodenal fluid sample is not subjected to a test for a pancreatic disease marker if the color depth thereof is lower than the standard color.

Abstract translation: 提供了一种专门选择具有高含有胰液的可能性的十二指肠液样品的方法，并且在检测胰腺疾病标记物之前通过评估样品的质量来评估对胰腺疾病标记物的检测的良好样品适合性的方法，以及方法 用于使用根据该方法选择的十二指肠液体样品检测胰腺疾病标记物。 即，提供一种选择用于检测胰腺疾病标记物的十二指肠液样品的方法，包括：（a1）将十二指肠液样品的颜色深度与规定的标准颜色进行比较的步骤，（b1）确定 如果十进制液体样品的颜色深度等于或高于标准颜色，则对十二指肠液样品进行胰腺疾病标记物的测试，但如果十进制液体样品的颜色 其深度低于标准颜色。

公开(公告)号：US20170290572A1

公开(公告)日：2017-10-12

申请号：US15094789

申请日：2016-04-08

Applicant: OLYMPUS CORPORATION

Inventor： Mari NAKATA ,  Hiromi SANUKI ,  Junichi MURAMATSU ,  Keita SHOJI

IPC: A61B10/02 ,  A61B8/12 ,  A61M5/32 ,  A61B10/00

CPC classification number: A61B10/0233 ,  A61B1/00112 ,  A61B1/0057 ,  A61B1/015 ,  A61B1/018 ,  A61B8/085 ,  A61B8/12 ,  A61B10/0045 ,  A61B2010/0061 ,  A61B2010/0216

Abstract: A method for collecting tissue includes a body fluid removal step in which a body fluid inside a pancreatic cyst is moved to an outside of the pancreatic cyst, an injecting step in which a liquid different from the body fluid is injected into the pancreatic cyst, a collecting step in which the liquid is collected from the pancreatic cyst, and a separating step in which tissue of an inner wall of the pancreatic cyst, which is contained in the liquid collected from the pancreatic cyst, is separated from the liquid.